BFEC
HSTO

Benjamin F. Edwards & Company’s Histogen Inc. Common Stock HSTO Stock Holding History

Benjamin F. Edwards & Company’s Portfolio HSTO Stock Details HSTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5
Closed – – 1943
2022
Q4 		$0 Buy
+5
New +$6 ﹤0.01% 1940

Other funds holding HSTO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Benjamin F. Edwards & Company's HSTO Position: Q1 2023 in Review

Benjamin F. Edwards & Company sold out of Histogen Inc. Common Stock (HSTO) in Q1 2023, closing a stake of 5 shares.

Benjamin F. Edwards & Company first reported a position in HSTO in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 14 funds tracked by Wall St. Rank hold HSTO as of Q1 2023.

  • Benjamin F. Edwards & Company reported no remaining Histogen Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 5 Histogen Inc. Common Stock shares in Q1 2023.
  • Benjamin F. Edwards & Company first reported a position in Histogen Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Histogen Inc. Common Stock position peaked at $0 in Q4 2022.
  • 14 funds tracked by Wall St. Rank held Histogen Inc. Common Stock as of Q1 2023.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2023, filed 27 Apr 2023.